Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis.

Furthermore, there was an evident trend to favor ICIs than control therapies in cancer patients with Pembrolizumab (younger: HR: 0.54, 95% CI: 0.42 to 0.68; older: HR: 0.72, 95% CI: 0.59 to 0.88) and Atezolizumab (younger: HR: 0.85, 95% CI: 0.75 to 0.95; older: HR: 0.66, 95% CI: 0.47 to 0.91) both in younger and older arm with statistically significance, but disfavor those in cancer patients who take Nivolumab (younger: HR: 0.79, 95% CI: 0.53 to 1.18; older: HR: 0.83, 95% CI: 0.59 to 1.18) and Ipilimumab (younger: HR: 0.95, 95% CI: 0.73 to 1.25; older: HR: 1.02, 95% CI: 0.86 to 1.21).

also in 268 other papers